The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Arnecke Sibeth Dabelstein

Work +49 69 979 885 0
Fax +49 69 979 885 85
Berlin, Dresden, Frankfurt am Main, Hamburg, Leer, Munich

Show all Pressemitteilungen

Unabhängige nationale Kanzlei entsteht: Arnecke Siebold und SIBETH schließen sich zu ARNECKE SIBET

June 2016

Frankfurt am Main/München, 1. September 2015

Heute ist die Verschmelzung vollzogen worden: ARNECKE SIBETH wird ab sofort von ihren Standorten in Frankfurt am Main, München, Berlin und Dresden gemeinsam tätig sein. Mit 35 Partnern und über 100 Anwälten zählt die Kanzlei nun zu den großen nationalen Kanzleien in Deutschland.

Durch die Fusion erwarten beide Kanzleien hohe Synergieeffekte für die sechs standortübergreifenden Praxisgruppen Corporate/M&A/Tax, Real Estate, Public Law, Employment, IP/IT Commercial und Transportation, Aviation & Logistics (TAL).

„Wir freuen uns, dass hier zwei Kanzleien zusammengehen, die perfekt harmonieren, sowohl in ihrer Kanzleikultur als auch in ihrer Beratungsqualität" sagt Thomas Richter, Gründungspartner bei SIBETH. „Und sich dabei noch perfekt ergänzen, was ein hohes Cross-Sellingpotenzial und Wachstumschancen mit sich bringt,“ bekräftigt Michael Siebold, Gründer und Managing Partner von Arnecke Siebold. Beide Partner sind überzeugt, “dass noch breiter aufgestellte Teams, eine höhere Spezialisierung und die größere Branchenbandbreite unseren Klienten zugute kommen werden”.

ARNECKE SIBETH wird zukünftig von einem Managementboard geführt, das in der Übergangsphase von je zwei Partnern der alten Kanzleien, u.a. Michael Siebold und Thomas Richter, besetzt wird.


ARNECKE SIBETH ist eine unabhängige nationale Full Service Kanzlei mit klaren Schwerpunkten. Experten unterschiedlicher Branchen bieten umfassende Beratung und partnerschaftliche Begleitung bei nationalen und internationalen Fragestellungen.

Die deutschlandweit agierende Kanzlei mit derzeit 35 Partnern beschäftigt rund 200 Mitarbeiter, davon über 100 berufstätige Rechtsanwälte, die Mandanten aus dem Mittelstand sowie Großunternehmen in speziellen Fragestellungen betreuen. ARNECKE SIBETH verfügt durch die Kanzleistandorte Frankfurt a.M., München und Berlin über Büros in drei wichtigen Anwaltsstandorten und hat eine vierte Niederlassung in Dresden.

2015 ist ARNECKE SIBETH aus einer Fusion der auf Wirtschaft spezialisierten Kanzleien SIBETH und Arnecke Siebold hervorgegangen. Im Hinblick auf finanzielle und personelle Kennzahlen befindet sich ARNECKE SIBETH dadurch nun unter den Top Adressen der führenden deutschen Anwaltskanzleien.

Ansprechpartner Presse:

Weitere Informationen finden sie unter

Co-Publishing weltweit

Rechtsentwicklungen und Neuigkeiten der führenden Anwälte in verschiedenen Jurisdiktionen. Für Beitrüge schicken Sie bitte eine Anfrage per Email an
  • China Drug Registration Regulation - Public consultation on amendment closes - March 2014

    In February 2014, the China Food and Drug Administration (“CFDA”) invited second-round comments from the public regarding proposed amendments to the China Drug Registration Regulations (“DRR”). One of the proposed amendments touches upon patent protection for drugs in China.
  • Revised NDRC Measures for Approval and Filing of Outbound Investment Projects - April 2014

    The National Development and Reform Commission ( NDRC ) released a new set of Management Measures for Approval and Filing of Outbound Investment Projects ( 境外投资项目核准和备案管理办法) ( New Measures ) on 8 April 2014. The New Measures take effect on 8 May 2014 and will replace the Interim Management Measures for Approval of Outbound Investment Projects ( 境外投资项目核准暂行管理办法) ( Original Measures ) which have been in force since 9 October 2004.
  • Insurance Update - CIRC Issues Insurance M&A Measures: What are the impacts and applications?

    On 21 March 2014, CIRC issued the Administrative Measures on the Acquisition and Merger of Insurance Companies (the Insurance M&A Measures ) which will take effect from 1 June 2014. The Insurance M&A Measures apply to M&A activities whereby an insurance company is the target for a merger or acquisition. The target insurance company could be either a domestic or a foreign invested insurer. However, the Insurance M&A Measures will not apply to any equity investment by insurance companies in non-insurance companies in China or in overseas insurance companies.
  • China issues new rules to regulate medical devices - May 2014

    The Regulations on Supervision and Administration of Medical Devices (in Chinese《医疗器械监督管理条例》, State Council Order No. 650) (the Medical Device Regulations) were amended by China's State Council on 31 March 2014 and will come into effect on 1 June 2014. This is the first amendment in more than a decade since the Medical Device Regulations were first promulgated in 2000, even though the amendment was initiated eight years ago in 2006. The 2014 amendment unveils reforms on the regulatory regime for medical devices market in China from various aspects.
  • Hong Kong: The evolving role of independent non-executive directors - May 2014

     In a recent speech given by Mr. Carlson Tong, Chairman of the Securities and Futures Commission, Mr. Tong pointed out that companies can improve corporate governance by attaching higher importance to the role of their board of directors as an internal gatekeeper. Mr. Tong said that this can be done more easily by having effective independent non-executive directors (INEDs) on the board.
  • Walking a fine line in China:Distinguishing between legitimate commercial deals and commercial bribe

    China in the 21st century exemplifies an atmosphere of great opportunity and intense competition. Against this backdrop, it has become increasingly common for businesses to adopt a variety of practices in order to make their products and services competitive. Such practices may include paying middle-men to promote sales and giving incentives to buyers directly. However, whilst revenue spikes are undoubtedly welcome, businesses should bear in mind the potential backlash arising out of these commercial arrangements. The risk that such arrangements may not comply with anti-bribery and corruption laws and therefore cause business significant damage in the long term should not be underestimated.
  • Competition law developments in East Asia - May 2014

    Authorities in Hong Kong have taken further steps in their deliberate approach to enforcing the Competition Ordinance. A little over a year after it was appointed, the Competition Commission released a report in which it provides a brief introduction to the Ordinance as well as a roadmap leading to its full entry into force. The report also explains how the Commission will prioritise its enforcement activities, and identifies the guidelines, policies and compliance tools which it plans to release before the Ordinance is enforced. Currently only some of the institutional provisions of the Ordinance are effective, allowing the Commission and the Competition Tribunal to prepare for enforcement.
  • Rise of the private healthcare sector - July 2014

    As of 2013, China had 9,800 private hospitals, representing almost half of the total number of hospitals in the country 1 . However, private hospitals still severely lag behind their public peers due to low utilisation, talent shortages and incomplete social insurance coverage. As part of China's ongoing healthcare reform initiatives, the Chinese government has set a goal to increase the share of patients treated by private hospitals to 20% by the end of 2015 2 .
  • Walking a Tightrope in Singapore - July 2014

    The world has no borders and distance is negligible for the technologically savvy criminal. Individuals with illicit funds to launder or terrorist activities to finance can, with the latest technology, transfer high volumes of money around the globe almost instantaneously and seek to conceal the origin or the destination of the funds.
  • Indonesia banking bill: proposed restrictions on foreign investment - July 2014

    Indonesia's House of Representatives is currently considering a new draft banking bill (the Banking Bill ) which, if passed into law in its current form, will: